1. Home
  2. Companies
  3. PCK
  4. Material Events

Painchek (ASX:PCK) — Material Events

ASX:PCK · 19 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major 7 articles Significant 10 articles Notable 2 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Major Score 90+
7
PainChek Breaks Ground with FDA Clearance and US Market LaunchHigh
PainChek secures FDA clearance, launches US market entry with strong ARR growth and Infant App expansion
26 Nov 2025 ·AGM Presentation ·90
PainChek Breaks Into US Market with First Customer After FDA NodHigh
PainChek Secures First US Customer Following FDA De Novo Clearance, Targeting $100M Aged Care Market
13 Oct 2025 ·ASX Announcement ·Unexpected ·90
PainChek’s FDA Clearance Unlocks $175M US Market and Infant App GrowthHigh
PainChek secures FDA clearance, expands US market access, and advances Infant App commercialization
31 Oct 2025 ·Quarterly Activities and Cashflow Report ·90
Significant Score 75–89
10
PainChek’s Scottish Trial Cuts Falls 40%, Projects £66M NHS SavingsMedium
PainChek's UK pilot shows strong clinical benefits and £66M healthcare savings, advancing global growth
17 Sept 2025 ·Business Update ·85
PainChek Accelerates US Rollout with First Sabra Deployments and 5.9% ARR GrowthMedium
PainChek reports 5.9% ARR growth, first US commercial deployments, and improved cash flow
29 July 2026 ·Quarterly Activities Report and Appendix 4C ·85
PainChek Secures FDA Clearance, Unlocking US $3bn RTM Market OpportunityMedium
PainChek gains FDA clearance for US RTM reimbursement, expands US market presence with strong global licence growth
30 Jan 2026 ·Quarterly Activities and Cashflow Report ·85
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.